Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orion OyjSTU:OFK +0.06%85 3-1 Month Momentum % is 4.58% as of Aug. 01, 2026. GuruFocus rates STU:OFK with a GF Score™ of 85/100 and a GF Value™ of €73.52 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 1,030 Drug Manufacturers companies, Orion Oyj ranks better than 76.31% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-08-01), Orion Oyj's 3-1 Month Momentum % is 4.58%.
The industry rank for Orion Oyj's 3-1 Month Momentum % or its related term are showing as below:
STU:OFK's 3-1 Month Momentum % is ranked better than 76.31% of 1030
companies
in the Drug Manufacturers industry
Industry Median: -8.59
vs STU:OFK: 4.58
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Orion Oyj 3-1 Month Momentum % Related Terms
STU:OFK vs LLY, JNJ, ABBV: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - General subindustry, Orion Oyj's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Oyj 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orion Oyj's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Orion Oyj's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Oyj (STU:OFK) has a 3-1 Month Momentum % of 4.58% as of Aug. 01, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Orion Oyj and its competitors. According to the industry distribution chart, Orion Oyj ranks #244 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 23.7%.
Is Orion Oyj's 3-1 Month Momentum % too high?
Orion Oyj's current 3-1 Month Momentum % is 4.58%. Based on the distribution chart, Orion Oyj ranks #244 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Orion Oyj has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Oyj's 3-1 Month Momentum % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Orion Oyj ranks #244 out of 1030 companies for 3-1 Month Momentum %. This places Orion Oyj in the top 24% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
A good 3-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Orion Oyj and its competitors. Orion Oyj's current 3-1 Month Momentum % is 4.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Oyj stock overvalued right now?
Based on GuruFocus' analysis, Orion Oyj (STU:OFK) is currently considered Modestly Overvalued. The stock's GF Value™ is €73.52, compared to a current price of €81.25 — trading 10.5% above its estimated fair value. The current 3-1 Month Momentum % is 4.58%. Orion Oyj's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Orion Oyj (STU:OFK), the current 3-1 Month Momentum % is 4.58% as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Oyj (STU:OFK) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Oyj stock appears to be overvalued.
The current stock price of €81.25 is trading 10.5% above its estimated GF Value™ of €73.52.
GuruFocus considers Orion Oyj to be Modestly Overvalued.
Key valuation signals for STU:OFK:
3-1 Month Momentum %: 4.58%
GF Value™: €73.52 vs. price of €81.25 (10.5% above fair value)
No single metric tells the full story. See the STU:OFK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Oyj is a globally operating Finnish pharmaceutical company that develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company predominantly focuses on treatments for central nervous system disorders, oncology, and respiratory diseases. Orion's customers include specialists and general practitioners, veterinarians, pharmacies, hospitals, and laboratories. The company mainly serves Finland but also has a presence in other European countries, North America and other countries.
85GF Score
Get the complete analysis for STU:OFK
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:OFK has been successfully added to your 
